This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
ebola virus | 1023 |
virus disease | 540 |
public health | 310 |
west africa | 276 |
sierra leone | 248 |
brain injury | 219 |
hemorrhagic fever | 211 |
evd outbreak | 206 |
neurocritical care | 182 |
ischemic stroke | 166 |
united states | 163 |
health care | 160 |
care unit | 156 |
infectious diseases | 154 |
democratic republic | 153 |
intensive care | 144 |
subarachnoid hemorrhage | 132 |
ebola outbreak | 130 |
status epilepticus | 127 |
world health | 126 |
patients admitted | 124 |
west african | 123 |
critical care | 123 |
health organization | 122 |
cardiac arrest | 120 |
evd survivors | 112 |
ebola hemorrhagic | 109 |
traumatic brain | 106 |
health workers | 104 |
virus infection | 102 |
evd patients | 102 |
cerebral edema | 99 |
patient care | 98 |
intracerebral hemorrhage | 98 |
healthcare workers | 97 |
infectious disease | 97 |
critically ill | 92 |
infection control | 87 |
haemorrhagic fever | 84 |
mean age | 82 |
poor outcome | 82 |
hospital mortality | 82 |
within hours | 79 |
risk factors | 79 |
brain death | 77 |
ill patients | 77 |
protective equipment | 74 |
intracranial pressure | 72 |
logistic regression | 71 |
respiratory syndrome | 71 |
health zones | 71 |
blood pressure | 70 |
acute ischemic | 69 |
personal protective | 69 |
acute respiratory | 67 |
symptom onset | 66 |
preparedness activities | 65 |
emergency department | 65 |
disease control | 63 |
chart review | 62 |
intracranial hemorrhage | 60 |
viral load | 59 |
severe acute | 59 |
ebola treatment | 58 |
clinical trials | 57 |
evd cases | 56 |
health services | 56 |
confirmed cases | 56 |
ebola outbreaks | 56 |
african countries | 56 |
mg dl | 55 |
ebola epidemic | 55 |
cohort study | 55 |
case report | 54 |
mechanical ventilation | 54 |
mortality rate | 54 |
interviewed trainers | 54 |
nonhuman primates | 53 |
functional outcome | 53 |
stroke patients | 52 |
aneurysmal subarachnoid | 52 |
evd outbreaks | 52 |
cord uid | 52 |
doc id | 52 |
reproduction number | 51 |
family members | 51 |
ich patients | 51 |
year old | 51 |
among patients | 50 |
patients treated | 50 |
contact tracing | 49 |
ebola response | 49 |
body fluids | 49 |
significant difference | 49 |
increased risk | 49 |
head ct | 47 |
health system | 47 |
statistically significant | 46 |
fatality rate | 46 |
severe tbi | 46 |
significantly higher | 46 |
case fatality | 46 |
midline shift | 46 |
medical center | 45 |
tbi patients | 45 |
ebola haemorrhagic | 45 |
current outbreak | 45 |
modified rankin | 45 |
clinical care | 45 |
psychological distress | 45 |
retrospective chart | 45 |
supportive care | 45 |
adult patients | 44 |
disease outbreak | 44 |
marburg virus | 44 |
lassa fever | 44 |
viral hemorrhagic | 44 |
control measures | 44 |
patients received | 43 |
data collection | 43 |
high risk | 43 |
disease outbreaks | 42 |
ng ml | 42 |
acute brain | 42 |
fruit bats | 41 |
healthcare institutions | 41 |
mg kg | 41 |
care workers | 41 |
affected countries | 41 |
highly infectious | 41 |
clinical outcomes | 41 |
incubation period | 40 |
glasgow coma | 40 |
primary outcome | 40 |
clinical trial | 40 |
clinical management | 40 |
emergency departments | 40 |
two groups | 40 |
health emergency | 39 |
red zone | 39 |
emergency physicians | 39 |
good outcome | 38 |
old male | 38 |
suspected cases | 38 |
patients receiving | 38 |
infected patients | 38 |
violent events | 38 |
one patient | 38 |
external ventricular | 38 |
temperature management | 37 |
infection prevention | 37 |
inclusion criteria | 37 |
biological weapons | 37 |
significantly associated | 36 |
icu los | 36 |
median age | 36 |
virus transmission | 36 |
may also | 36 |
delayed cerebral | 35 |
cerebral ischemia | 35 |
african outbreak | 35 |
care units | 35 |
evd epidemic | 35 |
hiv aids | 34 |
first hours | 34 |
clinical outcome | 34 |
emerging infectious | 34 |
retrospective cohort | 34 |
coma scale | 34 |
sample size | 34 |
communicable diseases | 34 |
treatment centers | 34 |
refractory status | 33 |
rankin scale | 33 |
outbreak size | 33 |
two patients | 33 |
blood flow | 33 |
confirmed evd | 33 |
patients may | 32 |
sah patients | 32 |
african ebola | 32 |
evd case | 32 |
regression analysis | 32 |
old female | 32 |
case definition | 32 |
hospital discharge | 32 |
ebola survivors | 31 |
patients undergoing | 31 |
independently associated | 31 |
observational study | 31 |
saharan africa | 31 |
factors associated | 31 |
retrospective review | 31 |
evd preparedness | 31 |
monoclonal antibodies | 31 |
health zone | 31 |
mortality rates | 31 |
immune response | 31 |
ebov infection | 31 |
acute care | 31 |
years old | 30 |
systematic review | 30 |
global health | 30 |
convalescent plasma | 30 |
ich score | 30 |
care settings | 30 |
consecutive patients | 30 |
burst suppression | 30 |
bodily fluids | 29 |
patients without | 29 |
direct contact | 29 |
within days | 29 |
ct scan | 29 |
patients presenting | 29 |
hypertonic saline | 29 |
related stigma | 29 |
phase i | 28 |
clinical features | 28 |
hematoma expansion | 28 |
spontaneous ich | 28 |
evd patient | 28 |
preparedness phase | 28 |
ebola patients | 28 |
decision making | 28 |
cerebral artery | 28 |
ventricular drain | 28 |
case series | 28 |
patient outcomes | 28 |
mental status | 28 |
neuro icu | 28 |
patient population | 28 |
marburg hemorrhagic | 28 |
poor outcomes | 28 |
least one | 27 |
response team | 27 |
health systems | 27 |
rhesus macaques | 27 |
white matter | 27 |
high mortality | 27 |
computed tomography | 27 |
cerebral perfusion | 27 |
electronic medical | 27 |
old man | 27 |
therapeutic hypothermia | 27 |
biological agents | 27 |
focus group | 27 |
ct head | 27 |
medical records | 27 |
icu stay | 26 |
case management | 26 |
human primates | 26 |
emergency nurses | 26 |
hemorrhagic fevers | 26 |
mcg ml | 26 |
odds ratio | 26 |
vesicular stomatitis | 26 |
quality improvement | 26 |
patients underwent | 26 |
respiratory tract | 26 |
adverse events | 26 |
stomatitis virus | 25 |
dendritic cells | 25 |
zaire ebola | 25 |
acodd members | 25 |
neurocritically ill | 25 |
organ failure | 25 |
social support | 25 |
preparedness system | 25 |
ct scans | 24 |
commonly used | 24 |
one year | 24 |
one study | 24 |
medical history | 24 |
clinical presentation | 24 |
time points | 24 |
rapid response | 24 |
regression model | 24 |
functional outcomes | 24 |
less likely | 24 |
highly hazardous | 24 |
middle east | 24 |
social media | 24 |
reported cases | 23 |
health facilities | 23 |
mm hg | 23 |
zaire ebolavirus | 23 |
viral haemorrhagic | 23 |
high dose | 23 |
transmission dynamics | 23 |
competing interests | 23 |
endothelial cells | 23 |
evd placement | 23 |
icu admission | 23 |
ebola vaccine | 23 |
middle cerebral | 23 |
control interventions | 23 |
hospital stay | 22 |
united nations | 22 |
analyzed using | 22 |
situation report | 22 |
ebola infection | 22 |
pregnant women | 22 |
hematoma volume | 22 |
blood samples | 22 |
sectional study | 22 |
magnetic resonance | 22 |
treatment center | 22 |
care patients | 22 |
brain tissue | 22 |
atrial fibrillation | 22 |
included patients | 22 |
suspected evd | 22 |
four patients | 22 |
glasgow outcome | 22 |
identified patients | 22 |
mri brain | 22 |
long term | 22 |
emergency medicine | 22 |
healthcare providers | 22 |
outbreak response | 22 |
asah patients | 22 |
emory university | 22 |
yellow fever | 21 |
communicable disease | 21 |
medical care | 21 |
single center | 21 |
retrospective analysis | 21 |
immune responses | 21 |
cerebral blood | 21 |
among evd | 21 |
ppe ensembles | 21 |
blood ebov | 21 |
hours post | 21 |
severe traumatic | 21 |
staff members | 21 |
central venous | 21 |
sexual transmission | 21 |
internalised stigma | 21 |
abdominal pain | 21 |
significantly lower | 21 |
elevated icp | 21 |
may require | 21 |
care facilities | 21 |
emergency response | 21 |
transcranial doppler | 21 |
limited data | 21 |
respiratory failure | 21 |
african evd | 21 |
confirmed case | 21 |
breast milk | 21 |
discharged home | 21 |
multivariate analysis | 21 |
ebov gp | 20 |
ongoing epidemic | 20 |
significant differences | 20 |
median time | 20 |
health worker | 20 |
intraventricular hemorrhage | 20 |
intracranial hypertension | 20 |
africa ebola | 20 |
stroke center | 20 |
academic medical | 20 |
old woman | 20 |
kidney injury | 20 |
epidemiological data | 20 |
ae hlct | 20 |
pilot study | 20 |
international concern | 20 |
ebola viruses | 20 |
confidence interval | 20 |
enacted stigma | 20 |
east respiratory | 20 |
health service | 20 |
targeted temperature | 20 |
outcome scale | 20 |
basal ganglia | 20 |
inflammatory response | 20 |
andexanet alfa | 20 |
past outbreaks | 20 |
us emergency | 20 |
response systems | 19 |
arrest patients | 19 |
cerebrospinal fluid | 19 |
isolation unit | 19 |
central africa | 19 |
biosafety level | 19 |
may provide | 19 |
biological warfare | 19 |
neutralizing antibodies | 19 |
healthcare system | 19 |
disease transmission | 19 |
national level | 19 |
ebola transmission | 19 |
severe ebola | 19 |
lessons learned | 19 |
carotid artery | 19 |
retrospectively reviewed | 19 |
multivariable logistic | 19 |
healthcare facilities | 19 |
acute stroke | 19 |
life support | 19 |
general public | 19 |
major bleeding | 19 |
first case | 19 |
medical record | 19 |
evd transmission | 19 |
marburg viruses | 19 |
heart rate | 18 |
study period | 18 |
data suggest | 18 |
serial interval | 18 |
clinical data | 18 |
three patients | 18 |
ebola situation | 18 |
per day | 18 |
days later | 18 |
traditional healers | 18 |
tertiary care | 18 |
new cases | 18 |
acute kidney | 18 |
hospital day | 18 |
immune system | 18 |
clinical deterioration | 18 |
risk communication | 18 |
days post | 18 |
urinary tract | 18 |
care team | 18 |
patients infected | 18 |
mass effect | 18 |
virus ebola | 18 |
nervous system | 18 |
additional file | 18 |
continuous eeg | 18 |
risk districts | 18 |
viral replication | 18 |
blood cultures | 18 |
fatal cases | 18 |
emergency medical | 18 |
high levels | 18 |
time series | 17 |
case counts | 17 |
three days | 17 |
syndrome coronavirus | 17 |
first time | 17 |
adverse effects | 17 |
independent predictors | 17 |
subdural hematoma | 17 |
surveyed trainees | 17 |
first months | 17 |
prospectively collected | 17 |
new onset | 17 |
five patients | 17 |
retrospective study | 17 |
ich volume | 17 |
temporal lobe | 17 |
mental health | 17 |
per patient | 17 |
care facility | 17 |
index case | 17 |
prediction interval | 17 |
ambulance services | 17 |
provide care | 17 |
resonance imaging | 17 |
virus outbreak | 17 |
hospital length | 17 |
general population | 17 |
hospital course | 17 |
comprehensive stroke | 17 |
health authorities | 17 |
hlcc conditions | 17 |
pupillary reactivity | 17 |
medical management | 17 |
health security | 17 |
first days | 17 |
central nervous | 17 |
palliative care | 17 |
surveillance response | 16 |
level containment | 16 |
ebola cases | 16 |
standard deviation | 16 |
blood glucose | 16 |
case reports | 16 |
team members | 16 |
prospective studies | 16 |
medical treatment | 16 |
hazardous communicable | 16 |
healthcare settings | 16 |
apnea testing | 16 |
statistical analysis | 16 |
neurological emergencies | 16 |
internal carotid | 16 |
reston ebolavirus | 16 |
pandemic influenza | 16 |
laboratory studies | 16 |
total number | 16 |
malignant cerebral | 16 |
must also | 16 |
mean arterial | 16 |
factor xa | 16 |
bush meat | 16 |
care professionals | 16 |
retrospective observational | 16 |
previous outbreaks | 16 |
arterial pressure | 16 |
mechanical thrombectomy | 16 |
situation reports | 16 |
may include | 15 |
venous access | 15 |
control group | 15 |
epileptiform discharges | 15 |
initial ct | 15 |
randomized controlled | 15 |
even though | 15 |
case definitions | 15 |
readily available | 15 |
collected data | 15 |
may lead | 15 |
healthcare worker | 15 |
renal failure | 15 |
basic reproduction | 15 |
several days | 15 |
time period | 15 |
care setting | 15 |
may result | 15 |
apnea test | 15 |
informed consent | 15 |
multivariate logistic | 15 |
clinical course | 15 |
exclusion criteria | 15 |
patients required | 15 |
interim guidance | 15 |
determine whether | 15 |
anoxic brain | 15 |
mass gatherings | 15 |
confirmed ebola | 15 |
acute neurological | 15 |
serum chloride | 15 |
genome sequences | 15 |
clinical research | 15 |
fatality rates | 15 |
care providers | 15 |
baseline characteristics | 15 |
study showed | 15 |
assessed using | 15 |
national institute | 15 |
providing care | 15 |
hemorrhagic transformation | 15 |
among ebola | 15 |
human transmission | 15 |
metabolic acidosis | 15 |
hemorrhagic stroke | 15 |
ring vaccination | 15 |
respiratory distress | 15 |
year period | 15 |
spot sign | 15 |
vasogenic edema | 15 |
animal models | 15 |
worse outcomes | 15 |
past medical | 15 |
cerebral infarction | 15 |
linear regression | 15 |
brain mri | 15 |
ppe donning | 15 |
evd infection | 14 |
optic nerve | 14 |
high viral | 14 |
standard precautions | 14 |
independent predictor | 14 |
month follow | 14 |
laboratory testing | 14 |
clinical manifestations | 14 |
face shield | 14 |
poorly understood | 14 |
intraparenchymal hemorrhage | 14 |
discharge disposition | 14 |
western africa | 14 |
platelet function | 14 |
eeg monitoring | 14 |
international health | 14 |
jui government | 14 |
ct angiogram | 14 |
mechanically ventilated | 14 |
authors declare | 14 |
outcomes included | 14 |
evd treatment | 14 |
code status | 14 |
health emergencies | 14 |
emergency preparedness | 14 |
local health | 14 |
patient developed | 14 |
organ donation | 14 |
surviving patients | 14 |
study aims | 14 |
avian influenza | 14 |
fatality ratio | 14 |
recent studies | 14 |
treatment centre | 14 |
risk factor | 14 |
calculated using | 14 |
aneurysmal sah | 14 |
pediatric patients | 14 |
injured patients | 14 |
data analysis | 14 |
university hospital | 14 |
viral rna | 14 |
side effects | 14 |
transmission chains | 14 |
care society | 14 |
controlled trial | 14 |
clinical observations | 14 |
clinical practice | 14 |
brain showed | 14 |
peripheral blood | 14 |
subdural hemorrhage | 14 |
equateur province | 14 |
evd survivor | 14 |
early warning | 14 |
spinal cord | 14 |
brain edema | 14 |
three months | 14 |
transmission rate | 14 |
cerebral vasospasm | 14 |
better understand | 14 |
data regarding | 14 |
patients requiring | 14 |
preliminary report | 14 |
fluid resuscitation | 13 |
doffing ppe | 13 |
remains unclear | 13 |
hlcc unit | 13 |
performed using | 13 |
posterior circulation | 13 |
favorable outcome | 13 |
time frame | 13 |
common cause | 13 |
host immune | 13 |
ebola viral | 13 |
neurology residents | 13 |
evd positive | 13 |
whole blood | 13 |
icu length | 13 |
icu patients | 13 |
patient characteristics | 13 |
icp monitoring | 13 |
risk assessment | 13 |
replacement therapy | 13 |
among health | 13 |
electrographic seizures | 13 |
filovirus disease | 13 |
important role | 13 |
eeg patterns | 13 |
neutralizing antibody | 13 |
missing data | 13 |
virus glycoprotein | 13 |
enrolled patients | 13 |
measured using | 13 |
secondary outcomes | 13 |
south africa | 13 |
units kg | 13 |
isolation units | 13 |
receiver operating | 13 |
trauma center | 13 |
may help | 13 |
low risk | 13 |
real time | 13 |
improve patient | 13 |
treated patients | 13 |
mcg kg | 13 |
may occur | 13 |
may present | 13 |
elevated intracranial | 13 |
patients enrolled | 13 |
pupil size | 13 |
functional status | 13 |
human ebola | 13 |
decompressive hemicraniectomy | 13 |
cerebral autoregulation | 13 |
neurological deficits | 13 |
gold standard | 13 |
among survivors | 13 |
serum sodium | 13 |
two days | 13 |
us department | 13 |
clinical seizures | 13 |
neurointensive care | 13 |
clinical staff | 13 |
sided weakness | 13 |
government hospital | 13 |
painful stimulation | 13 |
national institutes | 13 |
results suggest | 13 |
literature review | 13 |
septic shock | 13 |
acute phase | 13 |
brain injuries | 13 |
expert panel | 13 |
six months | 13 |
antiviral activity | 13 |
suspected ebola | 13 |
prospective study | 13 |
findings suggest | 13 |
biocontainment unit | 13 |
admission gcs | 13 |
neurological outcomes | 13 |
average age | 13 |
cynomolgus macaques | 12 |
virus infections | 12 |
observational cohort | 12 |
service utilisation | 12 |
com scientificreports | 12 |
univariate analysis | 12 |
occupational health | 12 |
healthy volunteers | 12 |
arterial verapamil | 12 |
higher mortality | 12 |
ebov replication | 12 |
acutely ill | 12 |
future outbreaks | 12 |
stigma among | 12 |
spontaneous intracerebral | 12 |
current state | 12 |
early identification | 12 |
pulmonary embolism | 12 |
infected person | 12 |
hyperosmolar therapy | 12 |
total outbreak | 12 |
significant improvement | 12 |
general practitioners | 12 |
affected health | 12 |
immediate post | 12 |
fever outbreaks | 12 |
viral loads | 12 |
patient management | 12 |
clinical characteristics | 12 |
negative pressure | 12 |
surgical intervention | 12 |
phase iii | 12 |
primary objective | 12 |
explanatory models | 12 |
patients experienced | 12 |
hospitalized patients | 12 |
humoral immunity | 12 |
previous studies | 12 |
endovascular treatment | 12 |
inpatient sample | 12 |
unfavorable outcome | 12 |
cases reported | 12 |
lumbar puncture | 12 |
patients met | 12 |
healthcare institution | 12 |
hlcc units | 12 |
risk patients | 12 |
two cases | 12 |
cell responses | 12 |
cerebral venous | 12 |
disseminated intravascular | 12 |
outbreak occurred | 12 |
wild animals | 12 |
prothrombin complex | 12 |
prior outbreaks | 12 |
conducted using | 12 |
ischemic strokes | 12 |
periodic discharges | 12 |
level isolation | 12 |
academic hospitals | 12 |
multiorgan failure | 12 |
field epidemiology | 12 |
improve outcomes | 12 |
interquartile range | 12 |
outcome group | 12 |
early stages | 12 |
nine patients | 12 |
higher rate | 12 |
median gcs | 12 |
american college | 12 |
health measures | 12 |
asymptomatic infection | 12 |
increased icp | 12 |
phase ii | 12 |
predictive value | 12 |
emory healthcare | 12 |
centralized care | 12 |
patients developed | 12 |
hospital complications | 12 |
waste management | 12 |
primary diagnosis | 12 |
descriptive statistics | 12 |
human infection | 12 |
disease process | 12 |
moyamoya disease | 12 |
health officials | 12 |
may benefit | 12 |
hong kong | 12 |
distress among | 12 |
pupillary light | 12 |
one month | 12 |
repeat imaging | 12 |
emerging pathogens | 12 |
vital signs | 12 |
neurologic outcome | 12 |
clinical variables | 12 |
limited resources | 12 |
secondary screening | 11 |
west nile | 11 |
neurosurgical intervention | 11 |
reverse transcription | 11 |
imaging findings | 11 |
nursing staff | 11 |
higher rates | 11 |
target temperature | 11 |
tract infections | 11 |
high morbidity | 11 |
best practices | 11 |
healthcare facility | 11 |
one health | 11 |
respiratory protection | 11 |
advice guideline | 11 |
operating procedures | 11 |
small number | 11 |
airborne transmission | 11 |
aids patients | 11 |
rapid advice | 11 |
day postexposure | 11 |
outcome measures | 11 |
central line | 11 |
made available | 11 |
nebraska biocontainment | 11 |
wide range | 11 |
evd affected | 11 |
comatose survivors | 11 |
met inclusion | 11 |
clinical suspicion | 11 |
will require | 11 |
evidence suggests | 11 |
qualitative research | 11 |
copies ml | 11 |
human services | 11 |
recombinant vesicular | 11 |
infectious individuals | 11 |
significantly different | 11 |
nonendemic countries | 11 |
blood products | 11 |
poor prognosis | 11 |
people living | 11 |
study using | 11 |
health professionals | 11 |
large vessel | 11 |
ketamine infusion | 11 |
increased mortality | 11 |
haemorrhagic fevers | 11 |
preparedness phases | 11 |
direct patient | 11 |
medical staff | 11 |
highly pathogenic | 11 |
coil embolization | 11 |
population density | 11 |
renal replacement | 11 |
diffuse cerebral | 11 |
brain herniation | 11 |
animal studies | 11 |
ethical issues | 11 |
timely manner | 11 |
ebov mak | 11 |
aerosol transmission | 11 |
previously reported | 11 |
comatose patients | 11 |
iv tpa | 11 |
well documented | 11 |
health agencies | 11 |
pui criteria | 11 |
higher risk | 11 |
two weeks | 11 |
lethal ebola | 11 |
nitric oxide | 11 |
patient days | 11 |
forward projections | 11 |
neurological injury | 11 |
clinical evaluation | 11 |
travel restrictions | 11 |
vaccine candidates | 11 |
family filoviridae | 11 |
nucleic acid | 11 |
one case | 11 |
treatment units | 11 |
altered mental | 11 |
task force | 11 |
disease ebola | 11 |
comfort care | 11 |
trend towards | 11 |
rhesus monkeys | 11 |
analysis showed | 11 |
day mortality | 11 |
anterior circulation | 11 |
hemorrhagic manifestations | 11 |
ae hlcts | 11 |
compared using | 11 |
community health | 11 |
higher incidence | 11 |
stroke scale | 11 |
natural reservoir | 11 |
hospital los | 11 |
among healthcare | 11 |
mathematical models | 11 |
intravascular coagulation | 11 |
propofol infusion | 11 |
tract infection | 11 |
positive patients | 11 |
municipal health | 11 |
stochastic model | 11 |
ct showed | 11 |
close contact | 11 |
last years | 11 |
xa levels | 11 |
readmission rate | 10 |
vte prophylaxis | 10 |
dead body | 10 |
also found | 10 |
controlled trials | 10 |
donning doffing | 10 |
good neurological | 10 |
study design | 10 |
i clinical | 10 |
study team | 10 |
training program | 10 |
neurological outcome | 10 |
infected patient | 10 |
cerebral hemodynamics | 10 |
light reflex | 10 |
many patients | 10 |
apache ii | 10 |
ebola pandemic | 10 |
refractory se | 10 |
significant association | 10 |
automated pupillometry | 10 |
current evd | 10 |
kg min | 10 |
large hemispheric | 10 |
myocardial infarction | 10 |
educational program | 10 |
three groups | 10 |
clinical presentations | 10 |
brain ct | 10 |
primary health | 10 |
sodium levels | 10 |
present study | 10 |
functional recovery | 10 |
diagnostic tests | 10 |
hemodynamic instability | 10 |
disease spread | 10 |
ethics committee | 10 |
previous reports | 10 |
phase trial | 10 |
full ppe | 10 |
neurosciences intensive | 10 |
prospective observational | 10 |
previously healthy | 10 |
new york | 10 |
mucous membranes | 10 |
hand hygiene | 10 |
neuroscience icu | 10 |
poor clinical | 10 |
good functional | 10 |
mass gathering | 10 |
tract hemorrhages | 10 |
amyloid angiopathy | 10 |
longer icu | 10 |
fxa activity | 10 |
functional connectivity | 10 |
showed diffuse | 10 |
developed countries | 10 |
ppe used | 10 |
febrile illness | 10 |
eeg data | 10 |
cervical spine | 10 |
retrospectively analyzed | 10 |
sudan ebola | 10 |
bypass surgery | 10 |
complex concentrate | 10 |
sinus thrombosis | 10 |
head showed | 10 |
biological threats | 10 |
take place | 10 |
higher level | 10 |
neurological exam | 10 |
ebolavirus infection | 10 |
control practices | 10 |
hemispheric infarction | 10 |
nerve sheath | 10 |
continuous infusion | 10 |
lutte contre | 10 |
chest pain | 10 |
resource utilization | 10 |
potential confounders | 10 |
therapeutic anticoagulation | 10 |
differential diagnosis | 10 |
patients included | 10 |
younger children | 10 |
ppe selection | 10 |
sodium chloride | 10 |
ebola preparedness | 10 |
virus persistence | 10 |
tissue oxygen | 10 |
outbreak zone | 10 |
may improve | 10 |
person transmission | 10 |
different types | 10 |
fever virus | 10 |
interviewed trainer | 10 |
decompressive craniectomy | 10 |
perfusion pressure | 10 |
primary endpoint | 10 |
three countries | 10 |
hemostatic efficacy | 10 |
generation sequencing | 10 |
ocular fluid | 10 |
cm use | 10 |
patients often | 10 |
health infrastructure | 10 |
high prevalence | 10 |
systolic blood | 10 |
died within | 10 |
thromboembolic events | 10 |
ptp transmission | 10 |
surgical decompression | 10 |
ventriculoperitoneal shunt | 10 |
study population | 10 |
secondary cases | 10 |
heart failure | 10 |
current ebola | 10 |
vaccine development | 10 |
data sets | 10 |
data collected | 10 |
least two | 10 |
regional office | 10 |
general hospital | 10 |
international response | 10 |
first reported | 10 |
specific gravity | 10 |
multivariable analysis | 10 |
hospital admission | 10 |
retrospectively identified | 10 |
eight patients | 10 |
one week | 10 |
health facility | 10 |
viral genome | 9 |
resource settings | 9 |
phe volume | 9 |
phe response | 9 |
fever patients | 9 |
care system | 9 |
confidence intervals | 9 |
outside hospital | 9 |
turned negative | 9 |
antiepileptic drugs | 9 |
treatment options | 9 |
developing countries | 9 |
growth rate | 9 |
tested positive | 9 |
verbal abuse | 9 |
time point | 9 |
south korea | 9 |
emergency room | 9 |
polymerase chain | 9 |
fcp health | 9 |
igf levels | 9 |
filovirus infections | 9 |
within one | 9 |
response efforts | 9 |
severe disease | 9 |
high case | 9 |
health status | 9 |
health surveillance | 9 |
patients showed | 9 |
survey participants | 9 |
approved drugs | 9 |
transfer patients | 9 |
plasma samples | 9 |
care area | 9 |
infect dis | 9 |
lassa virus | 9 |
patient safety | 9 |
ebola patient | 9 |
care medicine | 9 |
multimodal monitoring | 9 |
case count | 9 |
plasminogen activator | 9 |
respiratory symptoms | 9 |
treat patients | 9 |
survival rate | 9 |
ten patients | 9 |
following tbi | 9 |
clinical judgment | 9 |
highest level | 9 |
clinical significance | 9 |
nosocomial transmission | 9 |
renal disease | 9 |
ct brain | 9 |
symptoms onset | 9 |
cognitive impairment | 9 |
advanced ebola | 9 |
human resources | 9 |
million people | 9 |
vaccine expressing | 9 |
coma score | 9 |
suspected case | 9 |
icp mmhg | 9 |
health related | 9 |
patients survived | 9 |
care population | 9 |
days following | 9 |
neurologic injury | 9 |
cdc guidelines | 9 |
remains unknown | 9 |
zaire strain | 9 |
new world | 9 |
higher levels | 9 |
scoring system | 9 |
refresher training | 9 |
diabetes insipidus | 9 |
reproduction numbers | 9 |
healthcare neglect | 9 |
confi rmed | 9 |
infective endocarditis | 9 |
healthcare personnel | 9 |
eye protection | 9 |
right mca | 9 |
negative septicemia | 9 |
available data | 9 |
process model | 9 |
peer review | 9 |
virus vaccines | 9 |
trained staff | 9 |
mean time | 9 |
took place | 9 |
ebov rna | 9 |
branching process | 9 |
early mobilization | 9 |
rapid diagnostic | 9 |
declared ebola | 9 |
neurological deterioration | 9 |
severe evd | 9 |
viral infections | 9 |
rapid diagnosis | 9 |
medical centers | 9 |
cellular immunity | 9 |
may reflect | 9 |
reston virus | 9 |
study aimed | 9 |
human evd | 9 |
antibiotic therapy | 9 |
spontaneous circulation | 9 |
among others | 9 |
natural history | 9 |
underwent continuous | 9 |
reverse genetics | 9 |
rankin score | 9 |
wilcoxon rank | 9 |
body temperature | 9 |
ebola spread | 9 |
admission sbp | 9 |
recombinant human | 9 |
health interventions | 9 |
disease patients | 9 |
neurologic emergencies | 9 |
containment care | 9 |
staff member | 9 |
social isolation | 9 |
median ich | 9 |
early detection | 9 |
congo hemorrhagic | 9 |
diagnostic testing | 9 |
current epidemic | 9 |
medical services | 9 |
clinical studies | 9 |
initial gcs | 9 |
baseline demographics | 9 |
organization regional | 9 |
decision support | 9 |
chain reaction | 9 |
management team | 9 |
regression models | 9 |
travel history | 9 |
tissue plasminogen | 9 |
surgical masks | 9 |
hospitals described | 9 |
health response | 9 |
older age | 9 |
corpus callosum | 9 |
time window | 9 |
fecal management | 9 |
review committee | 9 |
nasal cannula | 9 |
national health | 9 |
epidemic growth | 9 |
effective care | 9 |
antiplatelet agents | 9 |
inpatient rehabilitation | 9 |
report data | 9 |
rna viruses | 9 |
explanatory model | 9 |
direct exposure | 9 |
received iv | 9 |
health centres | 9 |
quantitative eeg | 9 |
bioterrorist attack | 9 |
disease severity | 9 |
probable cases | 9 |
ill patient | 9 |
exposure prophylaxis | 9 |
increasingly used | 9 |
square test | 9 |
correlation coefficient | 9 |
drain placement | 9 |
sheath diameter | 9 |
medical personnel | 9 |
following acute | 9 |
mouse model | 9 |
demographic characteristics | 9 |
convulsive status | 9 |
congo ebola | 9 |
scale score | 9 |
rna polymerase | 9 |
reported case | 9 |
causative agent | 9 |
raised icp | 9 |
preparedness efforts | 9 |
tranexamic acid | 9 |
blood pressures | 9 |
onset seizures | 9 |
convalescent blood | 9 |
preventive measures | 9 |
significant morbidity | 9 |
nursing facility | 9 |
social network | 9 |
clinically significant | 9 |
case highlights | 9 |
disease prevention | 9 |
ischemic brain | 9 |
patient presenting | 9 |
elderly patients | 9 |
medical teams | 9 |
following day | 9 |
neuroscience intensive | 9 |
final analysis | 9 |
experimental treatments | 9 |
nonhuman primate | 9 |
acodd teams | 9 |
hospitals interviewed | 9 |
gastrointestinal symptoms | 9 |
central african | 9 |
medical education | 9 |
patients died | 9 |
united kingdom | 9 |
control strategies | 9 |
limited number | 9 |
clinical illness | 9 |
medical countermeasures | 9 |
small sample | 9 |
guidelines recommend | 9 |
dedicated neurocritical | 9 |
neuromuscular blockade | 9 |
phase orange | 9 |
multivariate analyses | 9 |
randomized clinical | 9 |
infection complicated | 9 |
retrospective case | 9 |
convalescent patients | 8 |
infectious agents | 8 |
broad spectrum | 8 |
care visits | 8 |
rare case | 8 |
disease survivors | 8 |
western area | 8 |
months post | 8 |
early clinical | 8 |
high level | 8 |
blood loss | 8 |
air travel | 8 |
often require | 8 |
current guidelines | 8 |
icp management | 8 |
studies showed | 8 |
higher mean | 8 |
biocontainment units | 8 |
criteria included | 8 |
antenatal care | 8 |
intracranial aneurysms | 8 |
grade sah | 8 |
creative commons | 8 |
implementation group | 8 |
rank sum | 8 |
asymptomatic ebola | 8 |
engineering controls | 8 |
skilled nursing | 8 |
additional training | 8 |
african epidemic | 8 |
studies suggest | 8 |
patient outcome | 8 |
health stroke | 8 |
eeg background | 8 |
van den | 8 |
death within | 8 |
line health | 8 |
transmission rates | 8 |
leading cause | 8 |
collaborative preparedness | 8 |
unclear whether | 8 |
protective immunity | 8 |
significant risk | 8 |
good outcomes | 8 |
bundibugyo ebolavirus | 8 |
human disease | 8 |
patients within | 8 |
recent outbreak | 8 |
age groups | 8 |
cell activation | 8 |
ct findings | 8 |
sampling frame | 8 |
goal sodium | 8 |
artery occlusion | 8 |
successful recanalization | 8 |
mortality among | 8 |
hospital acquired | 8 |
prospectively enrolled | 8 |
plasma levels | 8 |
despite aggressive | 8 |
refractory icp | 8 |
north kivu | 8 |
head trauma | 8 |
neurological recovery | 8 |
analysis included | 8 |
spine surgery | 8 |
excluded patients | 8 |
sporting events | 8 |
rousettus aegyptiacus | 8 |
effective treatment | 8 |
outbreak setting | 8 |
trainers described | 8 |
health education | 8 |
old child | 8 |
forest region | 8 |
may need | 8 |
may contribute | 8 |
i will | 8 |
i studies | 8 |
operating characteristic | 8 |
also known | 8 |
fever ebola | 8 |
chapter will | 8 |
illness onset | 8 |
identified using | 8 |
seek medical | 8 |
weighted imaging | 8 |
isolation precautions | 8 |
flow diversion | 8 |
response teams | 8 |
obstetric complications | 8 |
cerebral amyloid | 8 |
day course | 8 |
perihematomal edema | 8 |
case studies | 8 |
neurologic outcomes | 8 |
community engagement | 8 |
population size | 8 |
general health | 8 |
infected animals | 8 |
tissue factor | 8 |
hlcc facilities | 8 |
successful treatment | 8 |
metagenomic sequencing | 8 |
arterial blood | 8 |
left sided | 8 |
seasonal influenza | 8 |
iic patterns | 8 |
stroke centers | 8 |
emergency care | 8 |
twice daily | 8 |
presenting symptoms | 8 |
many people | 8 |
identify patients | 8 |
obstetric patient | 8 |
closely related | 8 |
airway protection | 8 |
stroke symptoms | 8 |
blood transfusion | 8 |
sars epidemic | 8 |
frontal lobe | 8 |
icu needs | 8 |
early mobility | 8 |
evd placed | 8 |
physical contact | 8 |
membrane oxygenation | 8 |
month period | 8 |
lymph nodes | 8 |
management protocols | 8 |
neurological complications | 8 |
kikwit outbreak | 8 |
therapeutic intervention | 8 |
filovirus infection | 8 |
study suggests | 8 |
africa evd | 8 |
median duration | 8 |
invasive procedures | 8 |
anthrax attacks | 8 |
standard operating | 8 |
amino acid | 8 |
enteral antihypertensive | 8 |
user fee | 8 |
appropriate treatment | 8 |
confirmed patients | 8 |
gad ab | 8 |
oral anticoagulant | 8 |
stochastic branching | 8 |
care delivery | 8 |
fluid balance | 8 |
previously described | 8 |
guinea pigs | 8 |
past ebola | 8 |
virus challenge | 8 |
clinical indications | 8 |
ebola care | 8 |
first week | 8 |
isolation facilities | 8 |
seizure activity | 8 |
nationally representative | 8 |
using data | 8 |
specific antibody | 8 |
patient demographics | 8 |
plasma igf | 8 |
patient underwent | 8 |
multimodality monitoring | 8 |
will need | 8 |
risks associated | 8 |
acute subdural | 8 |
distress syndrome | 8 |
knowledge test | 8 |
may serve | 8 |
cervical spinal | 8 |
cell types | 8 |
zone transmission | 8 |
postexposure prophylaxis | 8 |
neurological examination | 8 |
neurologic deterioration | 8 |
common complication | 8 |
dose ta | 8 |
family engagement | 8 |
european network | 8 |
repeat head | 8 |
staff must | 8 |
rift valley | 8 |
urban areas | 8 |
early post | 8 |
included age | 8 |
venous thrombosis | 8 |
comfort measures | 8 |
head injury | 8 |
cerebral herniation | 8 |
clinical case | 8 |
control efforts | 8 |
international airport | 8 |
strongly associated | 8 |
multimodal approach | 8 |
useful tool | 8 |
pregnant evd | 8 |
also include | 8 |
laboratory tests | 8 |
respiratory viruses | 8 |
imported cases | 8 |
oral rehydration | 8 |
seizure prophylaxis | 8 |
obstructive hydrocephalus | 8 |
laboratory findings | 8 |
mri revealed | 8 |
seizure control | 8 |
respiratory infections | 8 |
zika virus | 8 |
nationwide inpatient | 8 |
ct angiography | 8 |
anesthetic agents | 8 |
well established | 8 |
leone ebola | 8 |
annual meeting | 8 |
experimental treatment | 8 |
may increase | 8 |
extubation failure | 8 |
aeromedical evacuation | 8 |
use among | 8 |
dna vaccines | 8 |
endemic areas | 8 |
treating patients | 8 |
catheter days | 8 |
mean regx | 8 |
one day | 8 |
disease caused | 8 |
ebola emergency | 8 |
patients discharged | 8 |
isolation centre | 8 |
transfer time | 8 |
treated animals | 8 |
inhospital mortality | 8 |
disease epidemic | 8 |
monoclonal antibody | 8 |
influenza pandemic | 8 |
valley fever | 8 |
super refractory | 8 |
global outbreak | 8 |
major outbreaks | 8 |
coma recovery | 8 |
care hospitals | 8 |
pain scores | 8 |
per year | 8 |
onsd measurement | 8 |
evd management | 8 |
supplementary file | 8 |
one third | 8 |
ml min | 8 |
case study | 8 |
spectrum antiviral | 8 |
care services | 8 |
review board | 8 |
clinical decision | 8 |
surveillance system | 8 |
post injury | 8 |
sum test | 8 |
high grade | 8 |
baseline data | 8 |
northern uganda | 8 |
plasma exchange | 8 |
death declaration | 7 |
extremely high | 7 |
single dose | 7 |
epidemic curves | 7 |
recent study | 7 |
imaging revealed | 7 |
us cdc | 7 |
center retrospective | 7 |
clinical predictors | 7 |
type i | 7 |
institutional review | 7 |
effective means | 7 |
convalescent whole | 7 |
venous thromboembolism | 7 |
trend toward | 7 |
ct imaging | 7 |
institutional preparedness | 7 |
healthy adults | 7 |
management strategies | 7 |
systolic bp | 7 |
data points | 7 |
sars outbreak | 7 |
hyperexcitable patterns | 7 |
medical waste | 7 |
preparedness plan | 7 |
epidemic setting | 7 |
postexposure protection | 7 |
surgical procedures | 7 |
performance category | 7 |
hypoxic ischemic | 7 |
hydrogen peroxide | 7 |
blood cell | 7 |
gcs score | 7 |
vessel occlusion | 7 |
response rate | 7 |
venous sinus | 7 |
pupil reactivity | 7 |
complication rates | 7 |
six hours | 7 |
ventilated patients | 7 |
humoral responses | 7 |
restricted diffusion | 7 |
alternative medicine | 7 |
antibody titres | 7 |
hyperimmune globulins | 7 |
open access | 7 |
initial head | 7 |
significant increase | 7 |
thrombolytic therapy | 7 |
drc ministry | 7 |
among hiv | 7 |
urine specific | 7 |
world bank | 7 |
recent years | 7 |
right frontal | 7 |
staff training | 7 |
cdc recommendations | 7 |
term functional | 7 |
close proximity | 7 |
rhesus macaque | 7 |
affected areas | 7 |
medical equipment | 7 |
metabolite deaq | 7 |
tested negative | 7 |
patients hospitalized | 7 |
patients suspected | 7 |
exit screening | 7 |
global cerebral | 7 |
health questionnaire | 7 |
multiple patients | 7 |
traumatic stress | 7 |
neurostimulant medications | 7 |
ebola victims | 7 |
symptomatic patients | 7 |
contrast extravasation | 7 |
potential ebola | 7 |
point likert | 7 |
dendritic cell | 7 |
endotracheal intubation | 7 |
neurogenic shock | 7 |
nurses association | 7 |
social determinants | 7 |
ganglia ich | 7 |
research institute | 7 |
ebolavirus genus | 7 |
primary outbreak | 7 |
antiplatelet therapy | 7 |
care within | 7 |
inflammatory cytokines | 7 |
antimicrobial therapy | 7 |
report ebola | 7 |
informal healthcare | 7 |
dwi lesions | 7 |
nsicu patients | 7 |
household contacts | 7 |
survey results | 7 |
mca territory | 7 |
reference range | 7 |
may limit | 7 |
preliminary analysis | 7 |
exact test | 7 |
within minutes | 7 |
external situation | 7 |
interventions may | 7 |
posterior reversible | 7 |
experimentally infected | 7 |
emergency use | 7 |
countries affected | 7 |
infectious ward | 7 |
final manuscript | 7 |
hypertonic nacl | 7 |
reservoir hosts | 7 |
ocular ultrasound | 7 |
intravenous immunoglobulin | 7 |
delta activity | 7 |
international scientific | 7 |
exponential growth | 7 |
primary efficacy | 7 |
hospital settings | 7 |
poor functional | 7 |
well tolerated | 7 |
injury patients | 7 |
mg day | 7 |
response network | 7 |
subcortical myoclonus | 7 |
deceased patients | 7 |
large number | 7 |
fever outbreak | 7 |
ebolavirus outbreak | 7 |
high number | 7 |
demographic data | 7 |
lung pathogenesis | 7 |
obstetric population | 7 |
function testing | 7 |
urgent care | 7 |
ebola epidemics | 7 |
africa outbreak | 7 |
wild meat | 7 |
highly contagious | 7 |
infant mortality | 7 |
peripheral hospitals | 7 |
nmes hpro | 7 |
health regulations | 7 |
treating ebola | 7 |
phase yellow | 7 |
best practice | 7 |
one item | 7 |
following aneurysmal | 7 |
regression analyses | 7 |
medical complications | 7 |
health messages | 7 |
neurological icu | 7 |
viral disease | 7 |
potentially infected | 7 |
adverse effect | 7 |
evd care | 7 |
nonconvulsive seizures | 7 |
technical committee | 7 |
early tracheostomy | 7 |
patient viral | 7 |
following cardiac | 7 |
ongoing ebola | 7 |
global response | 7 |
every hours | 7 |
five days | 7 |
mweka outbreak | 7 |
specific antibodies | 7 |
sars coronavirus | 7 |
antibody responses | 7 |
study protocol | 7 |
jugular bulb | 7 |
social resistance | 7 |
level data | 7 |
seven patients | 7 |
den enden | 7 |
center study | 7 |
genetic material | 7 |
intravenous thrombolysis | 7 |
forest guinea | 7 |
systemic inflammatory | 7 |
disease surveillance | 7 |
burr hole | 7 |
level trauma | 7 |
oral swab | 7 |
iv rt | 7 |
southern sudan | 7 |
kg hr | 7 |
myeloid cells | 7 |
rhythmic delta | 7 |
green zone | 7 |
pregnant patient | 7 |
adjunctive therapy | 7 |
limited resuscitation | 7 |
per preparedness | 7 |
clinical samples | 7 |
xa inhibitor | 7 |
vte bundle | 7 |
initial presentation | 7 |
compassionate use | 7 |
frontline physicians | 7 |
ebola vaccines | 7 |
powered air | 7 |
clamp trial | 7 |
pulmonary edema | 7 |
statistical analyses | 7 |
stroke care | 7 |
publicly available | 7 |
unfavorable outcomes | 7 |
proper use | 7 |
additional information | 7 |
diabetes mellitus | 7 |
nursing students | 7 |
swab samples | 7 |
animal reservoirs | 7 |
hemorrhage patients | 7 |
chloride concentration | 7 |
cell culture | 7 |
surgical clipping | 7 |
blood vessels | 7 |
burial practices | 7 |
patient populations | 7 |
vpa levels | 7 |
human asymptomatic | 7 |
may play | 7 |
flow nasal | 7 |
secondary transmissions | 7 |
neighbouring health | 7 |
health doi | 7 |
left frontal | 7 |
will also | 7 |
medical facilities | 7 |
tertiary education | 7 |
care ultrasound | 7 |
acid amplification | 7 |
less common | 7 |
iv brv | 7 |
improve survival | 7 |
cerebral performance | 7 |
platelet count | 7 |
viral particles | 7 |
cardiopulmonary resuscitation | 7 |
neurosurgical patients | 7 |
sore throat | 7 |
activities per | 7 |
vaccination coverage | 7 |
venous catheters | 7 |
takotsubo cardiomyopathy | 7 |
brainstem reflexes | 7 |
population health | 7 |
mean duration | 7 |
brain code | 7 |
cell entry | 7 |
ebola holding | 7 |
emerging infections | 7 |
naturally occurring | 7 |
also identified | 7 |
evd preparations | 7 |
recent violent | 7 |
cerebral oxygen | 7 |
acodd deployment | 7 |
chimpanzee adenovirus | 7 |
eeg showed | 7 |
health record | 7 |
prognostic information | 7 |
immune activation | 7 |
pressure monitoring | 7 |
simulation exercises | 7 |
outcomes following | 7 |
clinical center | 7 |
appropriate ppe | 7 |
stroke severity | 7 |
hounsfield unit | 7 |
bleed day | 7 |
encephalopathy syndrome | 7 |
care must | 7 |
ipc measures | 7 |
vast majority | 7 |
hemorrhagic symptoms | 7 |
ceeg monitoring | 7 |
western african | 7 |
hunt hess | 7 |
hospital bed | 7 |
repeat ct | 7 |
early clamp | 7 |
clinical symptoms | 7 |
methods section | 7 |
suspect cases | 7 |
associated ich | 7 |
equatorial guinea | 7 |
ebola disease | 7 |
focused conversation | 7 |
face shields | 7 |
financial support | 7 |
negative results | 7 |
prior ich | 7 |
specific clinical | 7 |
interim analysis | 7 |
imaging showed | 7 |
antibody cocktail | 7 |
medical procedures | 7 |
effective reproduction | 7 |
organ procurement | 7 |
month functional | 7 |
younger age | 7 |
adjusted odds | 7 |
neurological emergency | 7 |
additional research | 7 |
infusion duration | 7 |
emerging diseases | 7 |
secondary brain | 7 |
ais patients | 7 |
icu care | 7 |
laboratory parameters | 7 |
txa administration | 7 |
lower mortality | 7 |
sudden onset | 7 |
likert scale | 7 |
close contacts | 7 |
may become | 7 |
andexanet bolus | 7 |
intracranial hypotension | 7 |
critical illness | 7 |
indicator data | 7 |
observational studies | 7 |
viral persistence | 7 |
infected individuals | 7 |
physical exam | 7 |
discharge mrs | 7 |
imported case | 7 |
district health | 7 |
ct demonstrated | 7 |
reversible encephalopathy | 7 |
prior studies | 7 |
african american | 6 |
ct score | 6 |
shared decision | 6 |
well described | 6 |
icp waveform | 6 |
infrared spectroscopy | 6 |
iv antibiotics | 6 |
patients aged | 6 |
ebola rna | 6 |
treating evd | 6 |
lower gcs | 6 |
standardized management | 6 |
survival rates | 6 |
well understood | 6 |
weapons convention | 6 |
mobile laboratories | 6 |
medical team | 6 |
may affect | 6 |
surveillance systems | 6 |
retrospectively collected | 6 |
diffuse astrocytoma | 6 |
civil war | 6 |
emerging disease | 6 |
improved outcomes | 6 |
ncc patients | 6 |
small interfering | 6 |
international study | 6 |
early treatment | 6 |
pupil index | 6 |
evd pathogenesis | 6 |
infarct size | 6 |
evd response | 6 |
spectrum antibiotics | 6 |
near future | 6 |
may offer | 6 |
acute severe | 6 |
antimicrobial prophylaxis | 6 |
little data | 6 |
care worker | 6 |
virus replication | 6 |
samples collected | 6 |
good vs | 6 |
sich patients | 6 |
life threatening | 6 |
ebov viral | 6 |
investigational drugs | 6 |
vs poor | 6 |
disease among | 6 |
particularly important | 6 |
mesial temporal | 6 |
aged years | 6 |
series analysis | 6 |
capital city | 6 |
pregnant woman | 6 |
human activated | 6 |
extracorporeal membrane | 6 |
human infections | 6 |
scale scores | 6 |
conflict zone | 6 |
fort detrick | 6 |
point scale | 6 |
eff orts | 6 |
hospital staff | 6 |
many countries | 6 |
icp elevation | 6 |
anoxic injury | 6 |
health department | 6 |
intravascular volume | 6 |
gastrostomy tube | 6 |
previous evd | 6 |
epileptiform activity | 6 |
relevant information | 6 |
authors read | 6 |
interview guide | 6 |
salt water | 6 |
admission ct | 6 |
often used | 6 |
simulation exercise | 6 |
emergency operations | 6 |
intrafamilial spread | 6 |
readmission scores | 6 |
affected area | 6 |
institutional affiliations | 6 |
training sessions | 6 |
hemorrhagic complications | 6 |
posterior fossa | 6 |
reversal agent | 6 |
waste generated | 6 |
seizure detection | 6 |
imaging studies | 6 |
tracing team | 6 |
cerebellar ich | 6 |
stranded rna | 6 |
mrs score | 6 |
congo haemorrhagic | 6 |
neurologic status | 6 |
pa patients | 6 |
care centers | 6 |
bed density | 6 |
patients whose | 6 |
received training | 6 |
may facilitate | 6 |
northern countries | 6 |
hospital dissemination | 6 |
neurosurgical procedures | 6 |
new diseases | 6 |
publically available | 6 |
infected persons | 6 |
yersinia pestis | 6 |
continuous electroencephalography | 6 |
double gloves | 6 |
relative infectiousness | 6 |
requiring centralized | 6 |
infectious complications | 6 |
literature search | 6 |
health concern | 6 |
male presented | 6 |
digital subtraction | 6 |
outcomes related | 6 |
strong inflammatory | 6 |
workup revealed | 6 |
widely used | 6 |
published maps | 6 |
time spent | 6 |
pupillary parameters | 6 |
inpatient hospice | 6 |
disease progression | 6 |
therapeutic interventions | 6 |
lymphocyte apoptosis | 6 |
bombali virus | 6 |
future research | 6 |
following commands | 6 |
thrombotic events | 6 |
antiepileptic drug | 6 |
liquid waste | 6 |
phase clinical | 6 |
group compared | 6 |
treatment unit | 6 |
among different | 6 |
wlds activity | 6 |
mixing parameter | 6 |
body fluid | 6 |
viral proteins | 6 |
high concentration | 6 |
cardiogenic shock | 6 |
unfolding threat | 6 |
disease may | 6 |
vaccine use | 6 |
significant reduction | 6 |
icu days | 6 |
pta duration | 6 |
acute stage | 6 |
age years | 6 |
acute illness | 6 |
next steps | 6 |
longer time | 6 |
surgical interventions | 6 |
failure assessment | 6 |
first line | 6 |
ensoetm recipients | 6 |
laboratory data | 6 |
reviewed literature | 6 |
well studied | 6 |
nature remains | 6 |
intravenous fluid | 6 |
epidemic preparedness | 6 |
lethal challenge | 6 |
epidemiology network | 6 |
may impact | 6 |
cultural practices | 6 |
bleeding complications | 6 |
left mca | 6 |
pulmonary disease | 6 |
clinical specimens | 6 |
outbreaks chronology | 6 |
also observed | 6 |
urinary catheter | 6 |
acute management | 6 |
epidemiological link | 6 |
new dwi | 6 |
laboratory features | 6 |
patients managed | 6 |
serial ct | 6 |
mayinga strain | 6 |
ensure adequate | 6 |
improvement project | 6 |
bioterrorist attacks | 6 |
exposed individuals | 6 |
medical futility | 6 |
homeland security | 6 |
brain temperature | 6 |
healthy subjects | 6 |
adverse drug | 6 |
neurological conditions | 6 |
improves outcome | 6 |
motor function | 6 |
isolation effectiveness | 6 |
prone diabetes | 6 |
patient must | 6 |
care areas | 6 |
sustained icp | 6 |
electronic health | 6 |
enhanced ppe | 6 |
monocytes macrophages | 6 |
following spine | 6 |
acute onset | 6 |
gi disorders | 6 |
median outbreak | 6 |
analysis using | 6 |
life cycle | 6 |
clinical experience | 6 |
virus vp | 6 |
aid workers | 6 |
soviet union | 6 |
moderate risk | 6 |
deep venous | 6 |
included studies | 6 |
preliminary data | 6 |
apache iii | 6 |
severe brain | 6 |
serum levels | 6 |
traumatic intracranial | 6 |
first described | 6 |
although many | 6 |
successfully treated | 6 |
unconscious patients | 6 |
surrogate decision | 6 |
lower rates | 6 |
enhanced surveillance | 6 |
tiered approach | 6 |
brainstem hemorrhage | 6 |
treatment centres | 6 |
vaccine coverage | 6 |
zoonotic origin | 6 |
direct care | 6 |
care training | 6 |
neurological monitoring | 6 |
factors affecting | 6 |
peak plasma | 6 |
outbreak resulting | 6 |
information system | 6 |
genome sequencing | 6 |
least hours | 6 |
seeking care | 6 |
acute hemorrhagic | 6 |
innate immunity | 6 |
prospective cohort | 6 |
rotterdam ct | 6 |
related ich | 6 |
infectious period | 6 |
secondary injury | 6 |
invasive icp | 6 |
jurisdictional claims | 6 |
adaptive immune | 6 |
appropriate infection | 6 |
extremely low | 6 |
larger prospective | 6 |
glioblastoma multiforme | 6 |
year later | 6 |
aneurysm treatment | 6 |
basic clinical | 6 |
injury requiring | 6 |
patient presented | 6 |
vascular access | 6 |
small molecule | 6 |
admission nihss | 6 |
vein thrombosis | 6 |
also developed | 6 |
botulinum toxin | 6 |
cranial nerve | 6 |
term care | 6 |
emergency neurological | 6 |
innate immune | 6 |
endovascular intervention | 6 |
remains neutral | 6 |
obstetric patients | 6 |
hospital care | 6 |
rbc transfusions | 6 |
complications associated | 6 |
surge capacity | 6 |
brain barrier | 6 |
group discussions | 6 |
vaccination program | 6 |
widely available | 6 |
meningioma resection | 6 |
study shows | 6 |
patient died | 6 |
healthcare staff | 6 |
brain revealed | 6 |
tissue oxygenation | 6 |
term outcomes | 6 |
mean length | 6 |
several studies | 6 |
acquired infections | 6 |
institutional protocol | 6 |
multilevel modeling | 6 |
neurologic exam | 6 |
mayo clinic | 6 |
evd may | 6 |
blood transfusions | 6 |
serotonin syndrome | 6 |
virus neutralization | 6 |
maximum serum | 6 |
impaired cerebral | 6 |
iii clinical | 6 |
family member | 6 |
brain biopsy | 6 |
saudi arabia | 6 |
clinical improvement | 6 |
response system | 6 |
test scores | 6 |
high suspicion | 6 |
significant changes | 6 |
outbreak alert | 6 |
showed significant | 6 |
dead patients | 6 |
ketosis prone | 6 |
emergency physician | 6 |
eeg system | 6 |
clinical response | 6 |
screening area | 6 |
care nurses | 6 |
genomic data | 6 |
proinflammatory cytokines | 6 |
retrospective data | 6 |
care hospital | 6 |
low dose | 6 |
factor prothrombin | 6 |
laboratory diagnosis | 6 |
high degree | 6 |
major epidemic | 6 |
controlled clinical | 6 |
infection may | 6 |
frontal lobes | 6 |
icp values | 6 |
oxygen saturation | 6 |
treatment regimen | 6 |
mean difference | 6 |
vertebral artery | 6 |
seven days | 6 |
clinical signs | 6 |
stroke prevention | 6 |
academic emergency | 6 |
health crisis | 6 |
data management | 6 |
will continue | 6 |
may reduce | 6 |
attending physicians | 6 |
wearing ppe | 6 |
jugular vein | 6 |
structured interviews | 6 |
activated protein | 6 |
patient remains | 6 |
time periods | 6 |
constriction velocity | 6 |
care provider | 6 |
also measured | 6 |
south sudan | 6 |
key indicator | 6 |
related variables | 6 |
acute non | 6 |
nurse practitioners | 6 |
relative risk | 6 |
trainer described | 6 |
significantly worse | 6 |
international community | 6 |
diagnosis codes | 6 |
aggressive care | 6 |
maternal mortality | 6 |
african field | 6 |
grade subarachnoid | 6 |
social distancing | 6 |
total visits | 6 |
years ago | 6 |
motor response | 6 |
dci risk | 6 |
clot formation | 6 |
highly fatal | 6 |
temperature screens | 6 |
ongoing evd | 6 |
fever screening | 6 |
five districts | 6 |
intravenous fluids | 6 |
optimal management | 6 |
hospital setting | 6 |
medical attention | 6 |
four days | 6 |
international development | 6 |
data elements | 6 |
highly trained | 6 |
postoperative di | 6 |
oral administration | 6 |
first study | 6 |
first known | 6 |
antiviral agents | 6 |
angiogram showed | 6 |
varying levels | 6 |
left eye | 6 |
animal model | 6 |
flow cytometry | 6 |
ventricular drainage | 6 |
procurement organization | 6 |
worse functional | 6 |
media coverage | 6 |
springer nature | 6 |
internal jugular | 6 |
evaluated using | 6 |
acute sci | 6 |
rural areas | 6 |
air emboli | 6 |
porous borders | 6 |
properly protected | 6 |
sympathetic storming | 6 |
coronary artery | 6 |
pui definitions | 6 |
intracranial monitoring | 6 |
response eeg | 6 |
bushmeat ban | 6 |
tissue injury | 6 |
military hospital | 6 |
densely populated | 6 |
marburg haemorrhagic | 6 |
electrolyte disturbances | 6 |
claims data | 6 |
spillover events | 6 |
body weight | 6 |
urgent need | 6 |
patient transport | 6 |
filovirus haemorrhagic | 6 |
tcd cus | 6 |
ebov detection | 6 |
treating team | 6 |
single patient | 6 |
transmission events | 6 |
basilar artery | 6 |
common among | 6 |
increased incidence | 6 |
phe expansion | 6 |
screening tool | 6 |
optimal timing | 6 |
three time | 6 |
neurological intensive | 6 |
cns infections | 6 |
guideline development | 6 |
major ht | 6 |
potential role | 6 |
high fever | 6 |
journal club | 6 |
manage patients | 6 |
study ebola | 6 |
neurologic intensive | 6 |
exposure risk | 6 |
viral clearance | 6 |
previously published | 6 |
continuous renal | 6 |
significantly reduced | 6 |
bedside care | 6 |
left temporal | 6 |
including deaths | 6 |
associated urinary | 6 |
outcomes including | 6 |
onset data | 6 |
filoviral hemorrhagic | 6 |
fatal outcome | 6 |
patient contact | 6 |
referral hospital | 6 |
pearson correlation | 6 |
interrupted time | 6 |
decision makers | 6 |
tube feeding | 6 |
petrous ica | 6 |
posterior cerebral | 6 |
dose steroids | 6 |
immune evasion | 6 |
neurological worsening | 6 |
unintended consequences | 6 |
isolation facility | 6 |
using standardized | 6 |
acute tbi | 6 |
piv placement | 6 |
neurological life | 6 |
deep vein | 6 |
surface area | 6 |
another important | 6 |
treatment group | 6 |
first cases | 6 |
evd knowledge | 6 |
will help | 6 |
scientificreports www | 6 |
nmb group | 6 |
recombinant adenovirus | 6 |
virus epidemic | 6 |
longer duration | 6 |
mild tbi | 6 |
evd insertion | 6 |
hemorrhagic disease | 6 |
patients diagnosed | 6 |
including ebola | 6 |
randomized trial | 6 |
become available | 6 |
catheter associated | 6 |
dose group | 6 |
focal deficits | 6 |
left hemiparesis | 6 |
fatal disease | 6 |
respiratory arrest | 6 |
online survey | 6 |
accidental exposure | 6 |
several factors | 6 |
cerebral glucopenia | 6 |
close collaboration | 6 |
working group | 6 |
hospital preparedness | 6 |
limited outbreak | 6 |
consensus statement | 6 |
case basis | 6 |
relatively high | 6 |
direct co | 6 |
laboratory workers | 6 |
fatal outcomes | 6 |
supplementary material | 6 |
evd vaccine | 6 |
endpoints included | 6 |
sdh patients | 6 |
prognostic uncertainty | 6 |
ill tbi | 6 |
free vpa | 6 |
central lines | 6 |
terrorist groups | 6 |
month outcome | 5 |
interprofessional team | 5 |
well beyond | 5 |
months prior | 5 |
timely detection | 5 |
absolute risk | 5 |
elevated serum | 5 |
local government | 5 |
imaging data | 5 |
collateral status | 5 |
contributing factors | 5 |
several weeks | 5 |
virus gp | 5 |
times higher | 5 |
lower extremity | 5 |
teaching hospital | 5 |
six patients | 5 |
support tools | 5 |
disease due | 5 |
therapeutic effect | 5 |
intraventricular alteplase | 5 |
concept trial | 5 |
much lower | 5 |
current recommendations | 5 |
ill traveler | 5 |
positive end | 5 |
final outbreak | 5 |
new process | 5 |
neuroimaging findings | 5 |
two separate | 5 |
clinic visits | 5 |
treatment groups | 5 |
drawn within | 5 |
clinical teams | 5 |
significantly reduce | 5 |
patients including | 5 |
motor vehicle | 5 |
xa level | 5 |
preventing transmission | 5 |
cerebellar edema | 5 |
filoviridae family | 5 |
vascular risk | 5 |
mg twice | 5 |
virus load | 5 |
nuclear scintigraphy | 5 |
convalescent ebola | 5 |
highly communicable | 5 |
per hour | 5 |
gcse group | 5 |
ebov transmission | 5 |
doff ppe | 5 |
acute intracranial | 5 |
evd outcome | 5 |
diastolic bp | 5 |
amniotic fluid | 5 |
gp gene | 5 |
many factors | 5 |
interdisciplinary team | 5 |
itd use | 5 |
better outcomes | 5 |
rapid spread | 5 |
diseases unit | 5 |
generation time | 5 |
raw data | 5 |
sdh evacuation | 5 |
ppe use | 5 |
hemorrhage expansion | 5 |
infected nhps | 5 |
large outbreak | 5 |
expiratory pressure | 5 |
pandemic potential | 5 |
intraventricular milrinone | 5 |
outcomes among | 5 |
dai grade | 5 |
cervical instability | 5 |
provide additional | 5 |
will likely | 5 |
neutralizing activity | 5 |
require intensive | 5 |
clinical nurse | 5 |
acute ich | 5 |
novel therapeutic | 5 |
severe cases | 5 |
randomised trial | 5 |
research ethics | 5 |
low levels | 5 |
osmolality ratio | 5 |
lobar ich | 5 |
nccu qi | 5 |
increased transmission | 5 |
appropriate use | 5 |
protocol adherence | 5 |
somewhat comfortable | 5 |
occupational safety | 5 |
soluble mediators | 5 |
rna editing | 5 |
ebolavirus strain | 5 |
continuous intravenous | 5 |
positive patient | 5 |
lateralized rhythmic | 5 |
generally considered | 5 |
characteristics included | 5 |
communicating artery | 5 |
pressure reactivity | 5 |
initial assessment | 5 |
emerging pathogen | 5 |
external triggering | 5 |
us hlius | 5 |
collected prospectively | 5 |
operating room | 5 |